期刊文献+

重组结核杆菌Ag85a-ESAT6融合蛋白的原核表达、纯化及其生物活性 被引量:4

Prokaryotic Expression and Biological Activity of Recombinant Mycobacterium tuberculosis Ag85a-ESAT6 Fusion Protein
原文传递
导出
摘要 目的原核表达、纯化重组结核杆菌Ag85a-ESAT6融合蛋白,并检测其生物活性。方法将Ag85a-ESAT6融合基因片段插入pET-28a(+)载体中,构建重组质粒pET-28a-Ag85a-ESAT6,转化大肠杆菌BL21(DE3),IPTG诱导表达。表达产物在变性条件下经Ni-琼脂糖凝胶层析柱纯化复性后,在体外对经5种不同类型的表达结核杆菌Ag85a和ESAT6的重组痘苗病毒免疫的小鼠脾淋巴细胞进行刺激,以MTT法检测脾淋巴细胞的增殖反应。结果重组质粒pET-28a-Ag85a-ESAT6经双酶切及测序鉴定证明构建正确;表达的重组融合蛋白相对分子质量约41000,主要以包涵体形式表达,表达量占菌体总蛋白的55.65%;纯化复性的重组融合蛋白纯度达95%以上,表达量约为1.2g/L发酵液,且具有良好的反应原性;与空痘苗病毒或生理盐水免疫的小鼠相比,5种重组痘苗病毒免疫的小鼠脾淋巴细胞与Ag85a-ESAT6融合蛋白共培养后,增殖活性明显升高(P<0.01)。结论成功利用原核系统表达了结核杆菌Ag85a-ESAT6融合蛋白,纯化复性的Ag85a-ESAT6融合蛋白具有生物学活性。 Objective To express recombinant Mycobacterium tuberculosis Ag85a-ESAT6 fusion protein in prokaryotic cells,purify the expressed product and determine its biological activity.Methods Ag85a-ESAT6 fusion gene fragment was inserted into vector pET-28a(+),and the constructed recombinant plasmid pET-28a-Ag85a-ESAT6 was transformed to E.coli BL21(DE3)for expression under induction of IPTG.The denaturalized expressed product was purified by Ni-agarose gel chromatography and renaturalized,then used for in vitro stimulation of spleno-lymphocytes of mice immunized with five kinds of recombinant vaccinia viruses expressing Ag85a and ESAT6 of M.tuberculosis.The proliferation of splenic lymphocytes was determined by MTT method.Results Both restriction analysis and sequencing proved that recombinant plasmid pET-28a-Ag85a-ESAT6 was constructed correctly.The expressed recombinant fusion protein,with a relative molecular mass of about 41 000,mainly existed in a form of inclusion body and contained 55.65% of total somatic protein.After purification and renaturation,the protein reached a purity of more than 95% and an expression level of about 1.2 g/L fermentation liquid,and showed good reactogenicity.As compared with those immunized with empty vaccinia virus or physiological saline,the proliferation activities of spleno-lymphocytes of mice immunized with the five kinds of recombinant vaccinia viruses increased significantly after co-culture with Ag85a-ESAT6 fusion protein(P 〈0.01).Conclusion Ag85a-ESAT6 fusion protein was successfully expressed by using prokaryotic system and showed biological activity after purification and renaturation.
出处 《中国生物制品学杂志》 CAS CSCD 2010年第11期1153-1157,共5页 Chinese Journal of Biologicals
基金 "艾滋病和病毒性肝炎等重大传染病防治"科技重大专项基金(2008ZX10003-013)
关键词 分枝杆菌 结核 AG85A ESAT6 原核细胞 基因表达 生物活性 Mycobacterium tuberculosis Ag85a ESAT6 Prokaryotic cells Gene expression Biological activity
  • 相关文献

参考文献10

二级参考文献40

  • 1温见翔,吴少庭,陈群,秦莉,袁仕善,黄达娜,张仁利,高世同.结核分枝杆菌ESAT-6蛋白的表达与纯化[J].中国人兽共患病学报,2006,22(1):39-42. 被引量:3
  • 2岳乔红,苏明权,杨军兰,程晓东,段艳,郝晓柯.以结核分枝杆菌38kD重组蛋白为抗原的血清学诊断[J].中国生物制品学杂志,2006,19(6):633-635. 被引量:5
  • 3奥斯伯 布伦特 等.精编分子生物学实验指南[M].北京:科学出版社,1998.37-38,55-68,589. 被引量:42
  • 4Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet, 1995, 346(8986) : 1339-1345. 被引量:1
  • 5Pereira SM, Dantas OM, Ximenes R, et al. BCG vaccine against tuberculosis: its protective effect and vaccination policies. Rev Saude Publica, 2007, 41 (Suppl 1 ) : 59-66. 被引量:1
  • 6Sutter G, Staib C. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr Drug Targets Infect Disord, 2003, 3 (3) : 263-271. 被引量:1
  • 7Romano M, Roupie V, Wang XM, et al. Immunogenicity and protective efficacy of tuberculosis DNA vaccines combining mycolyltransferase Ag85A and phosphate transport receptor PstS-s. Immunology, 2000, 118 (3) : 321-332. 被引量:1
  • 8Behr MA, Wilson MA, Gill WP, et al. Comparative genomics of BCG vaccines by whole genome DNA microarray. Science, 1999, 284(5419) : 1520-1523. 被引量:1
  • 9Fan X, Gao Q, Fu R. DNA vaccine encoding ESAT-6 enhances the protective efficacy of BCG against Mycobacterium tuberculosis infection in mice. Scand J Immunol, 2007, 66(5) : 523-528. 被引量:1
  • 10McShane H, Behboudi S, Goonetilleke N, et al. Protective Immunity against Mycobacterium tuberculosis induced by dendritic cells pulsed with both CD8 ^+ - and CD4^+ -T-cell epitopes from antigen 85A. Infect Immun, 2002, 70(3) : 1623-1626. 被引量:1

共引文献7

同被引文献46

  • 1姜燕,Azuma Kalu,吕昌龙,单风平.结核分枝杆菌Ag85A DNA的克隆与原核表达[J].微生物学杂志,2007,27(3):16-20. 被引量:3
  • 2Hoft DF.Tuberculosis vaccine development:goals,immunological design,and evaluation[J].Lancet,2008,372(9633):164-175. 被引量:1
  • 3Andersen P,Doherty TM.The success and failure of BCGimplications for a novel tuberculosis vaccine[J].Nat Rev Microbiol,2005,3(8):656-662. 被引量:1
  • 4Baumann S,Nasser Eddine A,Kaufmann SH.Progress in tuberculosis vaccine development[J].Curr Opin Immunol,2006,18(4):438-448. 被引量:1
  • 5Verheust C,Goossens M,Pauwels K,et al.Biosafety aspects of modified vaccinia virus Ankara(MVA)-based vectors used for gene therapy or vaccination[J].Vaccine,2012,30(16):2623-2632. 被引量:1
  • 6Drexler I,Staib C,Sutter G.Modified vaccinia virus Ankara as antigen delivery system:how can we best use its potential[J].Curr Opin Biotechnol,2004,15(6):506-512. 被引量:1
  • 7Stittelaar KJ,Kuiken T,de Swart RL,et al.Safety of modified vaccinia virus Ankara(MVA)in immune-suppressed macaques[J].Vaccine,2001,19(27):3700-3709. 被引量:1
  • 8Tameris MD,Hatherill M,Landry BS,et al.Safety and efficacy of MVA85A,a new tuberculosis vaccine,in infants previously vaccinated with BCG:a randomised,placebo-controlled phase 2b trial[J].Lancet,2013,381(9871):1021-1028. 被引量:1
  • 9Verreck FA,Vervenne RA,Kondova I,et al.MVA.85A boosting of BCG and an attenuated,pho P deficient M.tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques[J].PLo S One,2009,4(4):e5264. 被引量:1
  • 10Langermans JA,Doherty TM,Vervenne RA,et al.Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6[J].Vaccine,2005,23(21):2740-2750. 被引量:1

引证文献4

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部